Operability changes in patients with NSCLC after neoadjuvant chemotherapy and anti-PD-1/PD-L1.
Rattachement africain : es. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
8055 Background: The neoadjuvant (NA) treatment for non-small cell lung cancer (NSCLC) has evolved with the emergence of chemotherapy (CT) and immunotherapy (IO) combinations as the standard of care. However, limited data exist on the impact of these treatments on functional parameters. This is a multicenter retrospective study, focuses on respiratory function in NSCLC patients (pts) undergoing NA therapy. Methods: We conducted a multicenter study of NSCLC pts undergone NA from January 2021 to December 2023 with pre- and post-NA respiratory tests. They were treated with CT or CT-IO. Clinical, pathological and surgical variables were collected. Comparative analysis between DLCO (Diffusing Capacity for Carbon Monoxide), FEV1 (Forced Espiratory Volume in first second) and FVC (Forced Vital Capacity) pre- and post-NA in CT/CT-IO subgroups were studied. We performed a regression univariate analysis with variables influencing DLCO, FEV1 and FVC variations. Results: We included 159 patients from 13 hospitals. Median age was 70, with 67% men, 72% ECOG 0, and 93% smokers or ex-smokers. Squamous histology was present in 50.3%, and PD-L1 expression was balanced. Non-G12C KRAS mutation was the most common molecular finding (15%). Pre-NA treatment stages included IB (0.6%), IIA (0.6%), IIB (1.8%), IIIA (89%), and IIIB (6.9%). NA treatment comprised CT in 25% and CT-IO in 75%. Surgery was performed in 88.5% pts, with lobectomy as the most common procedure (82%). After surgery, ypTNM: cPR (35%); mPR (28.7%); ypN1 (10 %); ypN2 (7.9%). 20 pts did not surgery: persistent N2 (25%), M1 (10%), complications (15%) and functional inoperability (50%). No significant differences were found in median pre-NA DLCO, FEV1, and FVC between CT and CT-IO subgroups. However, post-NA DLCO showed a reduction in CTIO (69.7% vs. CT 77%, p=0.003), while post-NA FEV1 and FVC increased in CT-IO (FEV1: 88% vs. CT 81.8%, p=0.029; FVC: 100.6% vs. CT 91%, p=0.003). Variation rates from pre- to post-NA values indicated a trend towards DLCO reduction in CT-IO (13% vs. CT 8%, p=0.08), and an increase in FEV1 (5% vs. CT 0%, p=0.002) and FVC (4% vs. CT -1.2%, p=0.001). Complications during NA treatment showed no significant differences. 10 patients were ineligible for surgery, with functional deterioration more prominent in the CT-IO subgroup, though without statistical significance (p=0.091). Conversions to thoracotomy were more common in CT-IO (66.6% vs. CT 33.3%, p=0.49). Univariate regression analysis revealed trends towards significance between FVC and liver disease, renal disease, and type of NA, as well as between FEV1 and liver disease, BMI, type of NA, and patient outcomes. Conclusions: Significant differences in post-NA functional variables were observed between CT-IO and CT subgroups, including lower DLCO and higher FEV1/FVC in the CT-IO group. Prospective validation is essential to confirm these findings.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Operability changes in patients with NSCLC after neoadjuvant chemotherapy and anti-PD-1/PD-L1.
- Date Crossref
- 01/06/2024
- Éditeur
- American Society of Clinical Oncology (ASCO)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Hospital Universitario Puerta de Hierro Majadahonda pays non établi dans la noticeÉtablissement de santé
-
Hospital Universitario 12 De Octubre pays non établi dans la noticeÉtablissement de santé
-
Hospital Clínico San Carlos pays non établi dans la noticeÉtablissement de santé
-
Hospital General Universitario de Ciudad Real pays non établi dans la noticeÉtablissement de santé
-
Hospital Clínico Universitario de Valladolid pays non établi dans la noticeÉtablissement de santé
-
Hospital Universitario Fundación Jiménez Díaz pays non établi dans la noticeÉtablissement de santé
-
Instituto Cajal pays non établi dans la noticeStructure de recherche
-
Hospital Universitario Severo Ochoa pays non établi dans la noticeÉtablissement de santé
-
Hospital Universitario del Henares pays non établi dans la noticeÉtablissement de santé
-
Hospital Universitario Fundación Alcorcón pays non établi dans la noticeÉtablissement de santé
-
Hospital Universitario de Fuenlabrada pays non établi dans la noticeÉtablissement de santé
-
Hospital Universitario Infanta Leonor pays non établi dans la noticeÉtablissement de santé
Hospital Universitario Puerta de Hierro Majadahonda, Hospital Universitario 12 De Octubre et Hospital Clínico San Carlos, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.